Nissay Asset Management Corp Japan ADV boosted its stake in Elanco Animal Health (NYSE:ELAN) by 14.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,287 shares of the company’s stock after acquiring an additional 4,877 shares during the quarter. Nissay Asset Management Corp Japan ADV’s holdings in Elanco Animal Health were worth $843,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Primecap Management Co. CA increased its stake in Elanco Animal Health by 12.5% in the 1st quarter. Primecap Management Co. CA now owns 34,435,759 shares of the company’s stock valued at $771,017,000 after buying an additional 3,837,394 shares during the last quarter. Janus Henderson Group PLC increased its stake in Elanco Animal Health by 209.7% in the 1st quarter. Janus Henderson Group PLC now owns 30,788,858 shares of the company’s stock valued at $689,364,000 after buying an additional 20,846,120 shares during the last quarter. BlackRock Inc. increased its stake in Elanco Animal Health by 9.0% in the 1st quarter. BlackRock Inc. now owns 21,195,235 shares of the company’s stock valued at $474,562,000 after buying an additional 1,742,777 shares during the last quarter. State Street Corp increased its stake in Elanco Animal Health by 24.3% in the 1st quarter. State Street Corp now owns 12,639,827 shares of the company’s stock valued at $283,006,000 after buying an additional 2,472,266 shares during the last quarter. Finally, Aristotle Capital Management LLC acquired a new stake in Elanco Animal Health in the 1st quarter valued at $243,886,000. 99.77% of the stock is currently owned by institutional investors and hedge funds.

Shares of ELAN stock opened at $23.63 on Friday. The firm has a market capitalization of $9.43 billion, a P/E ratio of 31.51, a P/E/G ratio of 3.53 and a beta of 0.87. Elanco Animal Health has a twelve month low of $15.17 and a twelve month high of $33.92. The company has a quick ratio of 2.97, a current ratio of 4.41 and a debt-to-equity ratio of 0.31. The stock’s fifty day simple moving average is $22.20 and its 200 day simple moving average is $24.29.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Thursday, July 30th. The company reported $0.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.07. The firm had revenue of $586.30 million for the quarter, compared to the consensus estimate of $555.84 million. Elanco Animal Health had a positive return on equity of 4.83% and a negative net margin of 3.63%. As a group, equities research analysts expect that Elanco Animal Health will post 0.6 EPS for the current fiscal year.

ELAN has been the topic of several recent research reports. Citigroup lowered their price target on shares of Elanco Animal Health from $35.00 to $27.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Zacks Investment Research upgraded shares of Elanco Animal Health from a “sell” rating to a “hold” rating in a research note on Wednesday, July 8th. Bank of America lifted their price target on shares of Elanco Animal Health from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Cleveland Research lowered shares of Elanco Animal Health from a “neutral” rating to an “underperform” rating and set a $19.00 price objective on the stock. in a research note on Monday, July 27th. Finally, Barclays restated a “buy” rating and set a $25.00 price objective on shares of Elanco Animal Health in a research note on Wednesday, May 13th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company. Elanco Animal Health has an average rating of “Hold” and a consensus target price of $26.50.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Recommended Story: Dividend Yield

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.